Etiology of Translocations in Hematopoietic Cells

造血细胞易位的病因学

基本信息

批准号：
8290504
负责人：
Christine A. Richardson
金额：
$ 24.76万
依托单位：
UNIVERSITY OF NORTH CAROLINA CHARLOTTE
依托单位国家：
美国
项目类别：
财政年份：
2003
资助国家：
美国
起止时间：
2003-05-19 至 2014-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8290504
关键词：
11q23 Alkylating Agents Antigen Receptors Bone Marrow Cell Culture Techniques Cells Chromosomal Rearrangement Chromosomal translocation Chromosome Band Clinical DNA DNA Damage DNA Repair DNA Sequence Rearrangement DNA biosynthesis Development Diet Double Strand Break Repair Embryo Endonuclease I Etiology Etoposide Event Exposure to Frequencies Generations Genes Genetic Genetic Recombination Genome Genomics Health Hematopoietic Human Infant Knock-in Mouse Lead Lymphoid Cell MLL gene MLLT3 gene Malignant Neoplasms Mammalian Cell Measures Metabolism Molecular Monitor Mus Oncogenic Perinatal Exposure Prevention therapy Recombinants Reporter Research Risk Stem cells System Therapy-Related Acute Myeloid Leukemia Topoisomerase II Topoisomerase-II Inhibitor Translocation Breakpoint Treatment Protocols Yeasts base chemotherapeutic agent cohort embryonic stem cell endodeoxyribonuclease SceI in vivo inhibitor/antagonist insight irradiation leukemia leukemia/lymphoma leukemogenesis mouse model novel strategies peripheral blood programs repaired sarcoma soft tissue stem

项目摘要

DESCRIPTION (provided by applicant): The long-term objective of my research is to understand the influence of hematopoietic-specific developmental programs on the repair DNA damage such as double strand breaks (DSBs) and the initial molecular events that lead to translocations, which are a hallmark of leukemia, lymphoma, and soft-tissue sarcomas. DSBs are highly recombinogenic, increasing the exchange of information between two homologous DNA duplexes by several orders of magnitude; thus, mammalian cells are potentially at risk for rearrangements arising during DSB repair. Chromosomal DSBs result following exposure to irradiation, alkylating agents, and topoisomerase II (topoII) inhibitors that are common therapies in the treatment of human cancers. Treatment regimens that include the topoII inhibitor etoposide are associated with one class of therapy-related acute myeloid leukemia (t-AML) and chromosomal translocations involving the mixed lineage leukemia (MLL) gene on chromosome band 11q23. Similarity of 11q23 MLL breakpoints in t-AML and infant leukemias suggests an association between de novo infant leukemia and in utero exposure to topoII inhibitors. The list of potential topo II inhibitors is extensive, and it remains unclear which of these compounds have a direct potential to induce the chromosomal translocations observed in the clinical setting. Using a unique genetic system to determine the potential for repair of DSBs within the breakpoint cluster regions of the 11q23 MLL gene and common partner genes to result in chromosomal translocations, this proposal will (1) determine the potential for exposure to a range of topoII inhibitors to initiate chromosomal rearrangements within the breakpoint cluster region of the MLL and AF9 genes similar to those observed in the clinical setting; and (2) create a targeted mouse model to determine in vivo the potential for exposure to topoII inhibitors to initiate chromosomal rearrangements within the breakpoint cluster region of the MLL and AF9 genes as measured by the presence of MLL-AF9 genome rearrangements in bone marrow and peripheral blood. These approaches in both ex vivo cell culture and in vivo mouse models will provide significant insight into the initiation of potentially oncogenic chromosomal rearrangements and leukemogenesis. Unraveling the etiology and consequences of translocations may lead to new approaches to therapy and prevention. PUBLIC HEALTH RELEVANCE: Exposure to the topoisomerase II (topoII) inhibitors is associated with chromosomal translocations involving the mixed lineage leukemia (MLL) gene on chromosome band 11q23, one class of therapy-related acute myeloid leukemia (t-AML), and possibly de novo infant leukemias following in utero exposure to topoII inhibitors. The list of potential topo II inhibitors is extensive, and it remains unclear which of these compounds have a direct potential to induce the chromosomal translocations observed in the clinical setting. Our approaches in both ex vivo cell culture and in vivo mouse models will provide significant insight into the initiation of these oncogenic chromosomal translocations and leukemogenesis and may lead to new approaches to therapy and prevention.

描述（由申请人提供）：我研究的长期目标是了解造血特异性发育程序对修复 DNA 损伤（例如双链断裂 (DSB)）和导致易位的初始分子事件的影响，这是白血病、淋巴瘤和软组织肉瘤的标志。 DSB 具有高度重组性，可将两个同源 DNA 双链体之间的信息交换增加几个数量级；因此，哺乳动物细胞在 DSB 修复过程中可能面临重排的风险。暴露于辐射、烷化剂和拓扑异构酶 II (topoII) 抑制剂后会产生染色体 DSB，这些抑制剂是治疗人类癌症的常见疗法。包含拓扑异构酶 II 抑制剂依托泊苷的治疗方案与一类与治疗相关的急性髓性白血病 (t-AML) 和涉及染色体带 11q23 上的混合谱系白血病 (MLL) 基因的染色体易位相关。 t-AML 和婴儿白血病中 11q23 MLL 断点的相似性表明新生婴儿白血病与子宫内暴露于拓扑异构酶 II 抑制剂之间存在关联。潜在的拓扑 II 抑制剂的名单很广泛，目前尚不清楚这些化合物中哪些化合物具有直接诱导临床环境中观察到的染色体易位的潜力。使用独特的遗传系统来确定 11q23 MLL 基因和共同伴侣基因的断点簇区域内 DSB 修复导致染色体易位的可能性，该提案将 (1) 确定暴露于一系列拓扑异构酶抑制剂的可能性在 MLL 和 AF9 基因的断点簇区域内启动染色体重排，类似于临床环境中观察到的情况； (2) 创建一个靶向小鼠模型，以确定体内暴露于 topoII 抑制剂在 MLL 和 AF9 基因断点簇区域内启动染色体重排的潜力，通过骨髓中 MLL-AF9 基因组重排的存在来测量和外周血。这些在离体细胞培养和体内小鼠模型中的方法将为潜在致癌染色体重排和白血病发生的启动提供重要的见解。揭示易位的病因和后果可能会带来新的治疗和预防方法。公共卫生相关性：暴露于拓扑异构酶 II (topoII) 抑制剂与染色体易位相关，涉及染色体带 11q23 上的混合谱系白血病 (MLL) 基因，这是一类与治疗相关的急性髓系白血病 (t-AML)，并且可能会导致子宫内暴露于拓扑异构酶 II 抑制剂后出现新生婴儿白血病。潜在的拓扑 II 抑制剂的名单很广泛，目前尚不清楚这些化合物中哪些化合物具有直接诱导临床环境中观察到的染色体易位的潜力。我们在离体细胞培养和体内小鼠模型中的方法将为这些致癌染色体易位和白血病发生的启动提供重要的见解，并可能带来新的治疗和预防方法。